Dynamic contrast-enhanced (DCE) -MRI has been widely used to assess tumor responses to anticancer drugs. Ktrans, one of the pharmacokinetic parameters of DCE-MRI, reflects blood perfusion and permeability in tumor tissue and is a good indicator of perfusion assessment. However, conventional analyses of DCE-MRI do not reflect drug response well, since tumor is extremely heterogeneous. In this study, we have developed a new method for quantitatively assessing the heterogeneous response of tumors during anticancer treatment, and applied it to examine the drug response of E7130, a novel anti-cancer agent with spatiotemporal variation in human breast cancer xenograft model.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords